Literature DB >> 15183429

Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10.

Xiaoling Zhang1, Zebing Mao, Changlong Yu.   

Abstract

Gene therapy offers a radically different approach to the treatment of arthritis. We demonstrated that cDNA coding for human interleukin-1 receptor-antagonist protein (IL-1Ra) and cDNA coding for human interleukin-10 (IL-10) can be delivered, by ex vivo techniques, to the synovial lining of joints, intra-articular expression of gene significantly reduced cartilage matrix degradation and cartilage breakdown. To achieve this, lapine synoviocytes were first transduced in culture by retroviral infection. The genetically modified synoviocytes were then transplanted by intra-articular injection into the knee joints of OA rabbits, assay of joint lavages confirmed that the gene expression was not lost 14 days after transfer. Knees receiving the IL-1Ra gene had significantly reduced cartilage breakdown. Delivery of the IL-10 gene was less effective, having only a moderate effect on cartilage breakdown. When both genes were injected together, there was a greater inhibition of cartilage breakdown, suggesting that simultaneous gene delivery may be necessary to treat OA by targeting the activities of multiple inflammatory effectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183429     DOI: 10.1016/j.orthres.2003.12.007

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  34 in total

1.  Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.

Authors:  Anja Weimer; Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Janina Frisch; Anna Wezel; Jochen Jung; Dieter Kohn; Ernest F Terwilliger; Stephen B Trippel; Magali Cucchiarini
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 2.  Pharmacologic therapy for osteoarthritis--the era of disease modification.

Authors:  David J Hunter
Journal:  Nat Rev Rheumatol       Date:  2010-11-16       Impact factor: 20.543

3.  scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy.

Authors:  L R Goodrich; J C Grieger; J N Phillips; N Khan; S J Gray; C W McIlwraith; R J Samulski
Journal:  Gene Ther       Date:  2015-04-23       Impact factor: 5.250

4.  Osteoarthritis: A single injection of anakinra for treating knee OA?

Authors:  Johanne Martel-Pelletier; Jean-Pierre Pelletier
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

Review 5.  Are there promising biologic therapies for osteoarthritis?

Authors:  David J Hunter
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 6.  Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.

Authors:  Niamh Fahy; Eric Farrell; Thomas Ritter; Aideen E Ryan; J Mary Murphy
Journal:  Tissue Eng Part B Rev       Date:  2014-08-04       Impact factor: 6.389

Review 7.  New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options.

Authors:  Martin K Lotz; Virginia B Kraus
Journal:  Arthritis Res Ther       Date:  2010-06-28       Impact factor: 5.156

Review 8.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

Review 9.  Gene Delivery to Joints by Intra-Articular Injection.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Hum Gene Ther       Date:  2018-01       Impact factor: 5.695

Review 10.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.